Affiliation:
1. 3BIGS Co., Ltd., Hwaseong 18469, Republic of Korea
2. Department of Applied Chemistry, Kyung Hee University, Yongin 17410, Republic of Korea
3. Holoce Ecosystem Conservation Research Institute, Hweongsung 25257, Republic of Korea
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease which requires continuous treatment due to its relapsing nature. The current treatment includes steroids and nonsteroidal agents targeting inflammation but long-term administration causes various side effects such as skin atrophy, hirsutism, hypertension and diarrhea. Thus, there is an unmet need for safer and effective therapeutic agents in the treatment of AD. Peptides are small biomolecule drugs which are highly potent and remarkably have less side effects. Parnassin is a tetrapeptide with predicted anti-microbial activity curated from Parnassius bremeri transcriptome data. In this study, we confirmed the effect of parnassin on AD using a DNCB-induced AD mouse model and TNF-α/IFN-γ-stimulated HaCaT cells. In the AD mouse model, topical administration of parnassin improved skin lesions and symptoms in AD mice, such as epidermal thickening and mast cell infiltration, similar to the existing treatment, dexamethasone, and did not affect body weight, or the size and weight of spleen. In TNF-α/IFN-γ-stimulated HaCaT cells, parnassin inhibited the expression of Th2-type chemokine CCL17 and CCL22 genes by suppressing JAK2 and p38 MAPK signaling kinases and their downstream transcription factor STAT1. Parnassin also significantly reduced the gene expression of TSLP and IL-31, which are pruritus-inducing cytokines. These findings suggested that parnassin alleviates AD-like lesions via its immunomodulatory effects and can be used as a candidate drug for the prevention and treatment of AD because it is safer than existing treatments.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference51 articles.
1. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”;Davidson;J. Allergy Clin. Immunol.,2019
2. Events in Normal Skin Promote Early-Life Atopic Dermatitis-The MPAACH Cohort;Sherenian;J. Allergy Clin. Immunol. Pract.,2020
3. Salvati, L., Cosmi, L., and Annunziato, F. (2021). From Emollients to Biologicals: Targeting Atopic Dermatitis. Int. J. Mol. Sci., 22.
4. Japanese guidelines for atopic dermatitis 2020;Katoh;Allergol. Int.,2020
5. The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study;Hawro;J. Am. Acad. Dermatol.,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献